https://www.selleckchem.com/products/adt-007.html
Injection site pain, hematoma, anesthesia/numbness, erythema, and swelling/edema were the most common AEs. There was no difference in their prevalence between both doses of DOC.Conclusions DOC is effective and safe for SMF reduction with no differences between doses of 1 and 2 mg/cm2.Budesonide is one of the intranasal corticosteroids, referred as first-line therapy for allergic rhinitis. Its determination is a challenging task due to its extremely low plasma levels, which limits the progress in the investigation of pharmacokinetics and
Like
Comment
Share
